van Zwieten P A, Mathy M J, Thoolent M J, Wilffert B, de Jonge A, Timmermans P B
J Hypertens Suppl. 1984 Dec;2(3):S539-41.
The interaction with alpha- and beta-adrenoceptors, and the antihypertensive and hypotensive effects of urapidil were studied in various animal models. Urapidil reduced the mean arterial pressure (MAP) of conscious normotensive and spontaneously hypertensive rates after oral administration. Urapidil antagonized alpha 1- and alpha 2-adrenoceptor-mediated vasoconstriction in pithed rats, elicited by cirazoline and B-HT 920, respectively. Urapidil itself caused pressor responses of limited magnitude at high doses in pithed rats, which were not blocked by yohimbine, prazosin or ketanserin. Urapidil displayed partial beta 1-adrenoceptor intrinsic activity in pithed rats. Urapidil was more potent in reducing MAP after infusion via the vertebral artery as compared to infusion via the femoral artery of chloralose-anaesthetized cats. The results suggest that urapidil reduces blood pressure via blockade of peripheral vascular alpha-adrenoceptors, and beta-receptor blockade. A centrally mediated hypotension not involving alpha 2-adrenoceptors may contribute to the antihypertensive effect.
在多种动物模型中研究了乌拉地尔与α和β肾上腺素能受体的相互作用以及其降压和低血压作用。口服给药后,乌拉地尔降低了清醒正常血压大鼠和自发性高血压大鼠的平均动脉压(MAP)。乌拉地尔分别拮抗了在脊髓麻醉大鼠中由可乐定和B-HT 920引起的α1和α2肾上腺素能受体介导的血管收缩。在脊髓麻醉大鼠中,高剂量的乌拉地尔本身会引起幅度有限的升压反应,而育亨宾、哌唑嗪或酮色林均不能阻断该反应。乌拉地尔在脊髓麻醉大鼠中表现出部分β1肾上腺素能受体内在活性。与在氯醛糖麻醉猫中经股动脉输注相比,经椎动脉输注后乌拉地尔在降低MAP方面更有效。结果表明,乌拉地尔通过阻断外周血管α肾上腺素能受体和β受体来降低血压。一种不涉及α2肾上腺素能受体的中枢介导的低血压可能有助于其降压作用。